Market Signal Briefing

In brief
Jibreel Pratt has been sentenced to nine years in federal prison after pleading guilty to concealing Bitcoin donations intended for ISIS.
The scheme involved recording a pledge of allegiance to ISIS, sending BTC payments, and providing tactical documents on weaponizing drones and organizing intelligence operations.
Pratt used a privacy-focused VPN and encryption software to mask his Bitcoin transfers, according to authorities.
A Detroit man who operated "in the shadows" while attempting to join and finance ISIS through crypto has been sentenced to nine years in federal prison, amid federal efforts to dismantle digital terrorism financing networks.

Jibreel Pratt pleaded guilty in July to two counts of concealing crypto donations he intended for the Islamic State of Iraq and Al-Sham, according to a statement by the U.S. Attorney's Office for the Eastern District of Michigan.

"Mr. Pratt is the latest traitor who—in his own words—operated 'in the shadows,” U.S. Attorney Jerome F. Gorgon, Jr. said in the Thursday statement. "And we will continue to stand guard because he may not be the last."

Pratt’s scheme began in February 2023 when he contacted someone he believed was an ISIS operative, who was in fact a confidential federal source.

A Confidential Human Source (CHS) is an individual who secretly provides information or assistance to law-enforcement agencies, often working undercover to help investigators gather evidence without revealing their identity.

Over the following months, Pratt expressed his commitment to the terrorist organization by recording a video pledging allegiance to ISIS's leader, according to the statement.

In March and May 2023, he transferred Bitcoin to the source, believing the funds would help pay for other recruits' travel to join ISIS or support someone preparing to commit violence in the group's name.

Pratt supplied the source with extensive handwritten notes and documents detailing operational strategies, including proposals for weaponizing drones and remote-controlled cars with explosives, organizing intelligence networks, and strengthening air defense capabilities.

To avoid detection, Pratt routed his BTC transfers through a privacy-focused VPN and used encryption software to hide transaction details and private keys.

“The sentencing should send a strong message to anyone seeking to support foreign terrorist organizations, via financial means or otherwise, that the FBI will not stand idly by and allow this activity to occur within the United States," FBI Special Agent in Charge Jennifer Runyan said in the statement.

Targeting extremist crypto fundingPratt's conviction comes amid a strengthened federal campaign targeting the use of crypto to fund extremist groups.

In May, a Virginia man received 30 years in prison for channeling over $185,000 in crypto to ISIS operatives in Syria between 2019 and 2022.

The Justice Department seized more than $200,000 in crypto linked to Hamas in March, part of a network authorities said has laundered over $1.5 million since late 2024.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Ethereum is caught between heavy selling from major players and fresh whale demand at a fragile $3,200 support zone. As Binance and BlackRock offload about $1 billion in ETH, large spot orders and key chart levels now decide the token’s next move.

Binance and BlackRock extend heavy ETH outflows as $1B leaves walletsFresh data from Arkham shows a sharp wave of Ethereum outflows from major Binance wallets in the past few hours, adding pressure to a trend that has unfolded for three straight days. Several Binance hot wallets moved large batches of ETH to market-maker addresses and exchanges, signaling continued selling activity as traders track the scale of withdrawals.

In the last hour, multiple transactions above $1 million each moved from Binance’s hot wallets toward Wintermute, Bybit and other settlement addresses. One transfer sent 1,205 ETH, while another pushed 1,133 ETH to Wintermute. Additional outflows included 550 ETH, 688 ETH and several smaller batches that followed the same pattern. These movements came as part of a broader series of ETH transfers leaving Binance throughout the morning.

At the two-hour mark, more sizable flows appeared. One wallet sent 1,114 ETH to Wintermute, while another moved 717 ETH to an external address before additional flows routed toward OKX and MEXC deposit wallets. The continuous transfers point to sustained pressure across centralized exchanges as liquidity shifts into trading venues or market-maker accounts.

Arkham ETH Outflows Dashboard. Source: Arkham/x

Rekt Fencer highlighted the acceleration in a separate update, noting that Binance and BlackRock offloaded roughly $1 billion worth of ETH over the last 10 hours. He added that both players have been selling consistently for three days, raising questions about why large holders are reducing exposure while ETH trades near key technical support.

Whales return to ETH spot markets as large order clusters re-emergeMeanwhile, Ethereum’s spot market is seeing a new wave of large-sized orders, according to fresh CryptoQuant data shared by analyst CryptoGoos. The chart shows a clear pickup in big-whale activity, with green and dark-green clusters appearing again after a quiet stretch earlier in the quarter.

Ethereum Spot Average Order Size. Source: CryptoQuant/X

The renewed concentration of large orders comes as ETH trades near a key support area that has shaped recent volatility. The data highlights strong participation from big wallets rather than retail traders, marking a notable shift in the order-flow profile. At the same time, the average spot order size has climbed back toward levels last seen during the early-2024 accumulation period.

These clusters indicate whales are actively positioning while the broader market digests recent selling pressure across exchanges. The appearance of steady large orders suggests that high-volume players are building exposure during a period of compressed price action, adding another layer to Ethereum’s current market structure.

Ethereum steadies at $3,200 as traders watch key support zoneEthereum is consolidating around the $3,200 level, a price area that chart analysts describe as a pivotal line for short-term direction. Fresh analysis from TedPillows shows ETH holding inside a narrow band after a series of sharp moves earlier in the week.

Ethereum Price Support and Resistance Map. Source: TedPillows

The chart highlights $3,200 as the immediate support that continues to absorb sell pressure. ETH has tested this zone multiple times, creating a tight consolidation structure that now shapes the next move. If the level holds, the chart outlines potential relief bounces toward resistance zones between $3,380 and $3,700, where previous breakdown points sit.

Below the current range, Ethereum faces a cluster of deeper support levels near $3,050 and $2,915. A clean break through $3,200 would put those lower zones back in play, signaling a broader shift in momentum as the market digests heavy exchange outflows and renewed volatility.

The setup places added focus on ETH’s ability to maintain stability around this midpoint area, with traders tracking whether buyers can prevent a move below the $3,000 threshold.

The cryptocurrency market is experiencing a wave of declines, leaving investors concerned as the Bitcoin, Ethereum, and Dogecoin prices fall sharply. Despite experiencing a period of recovery earlier this week, all three digital assets are now facing renewed downward pressure. The latest price declines are driven by both macroeconomic uncertainty and internal market factors, underscoring how sensitive the crypto market remains to changes in investor sentiment. 

FED Skepticism Fuel Decline In Bitcoin, Ethereum, And Dogecoin
The recent decline in cryptocurrency prices comes amid growing doubts over the Federal Reserve’s (FED) approach to interest rates. Recent remarks from FED officials, including the President of the Federal Reserve Bank of Minneapolis, Neel Kashkari, have cast uncertainty on whether the central bank will deliver a third consecutive easing of policy during the December FOMC meeting. 

According to Bloomberg reports, Kashkari noted that recent economic data suggested more resilience than was initially anticipated, sparking a debate over the necessity of further rate cuts. This cautious stance has unsettled financial markets, causing investors to reconsider earlier positions as former expectations of a rate now appear uncertain. 

Notably, Bitcoin, Ethereum, and Dogecoin have reacted sharply to the prevailing sentiment caused by the doubts in monetary easing. Their prices have plummeted, accelerating the broader correction that has been dragging on for months. This decline is also being augmented by large-scale whale sell offs and lingering ambiguity surrounding new developments in the previous US government shutdown. 

How Much BTC, ETH, And DOGE Declined This Week
In addition to macroeconomic factors, market dynamics are also contributing to crypto losses. CoinMarketCap’s data shows that the Bitcoin price crashed below $97,000 for the first time since May 2025. It has fallen more than 5% over the week and dropped another 6.4% in a single day. 

Amidst this decline, long-term BTC holders are reportedly selling at record levels, fueling the downtrend. Additionally, institutional demand is weakening while investor sentiment has turned negative. Even Spot Bitcoin ETF activity is plummeting, recording over $866.7 million in net outflows yesterday—the second largest in its history.  

Ethereum has also been hit hard, losing more than 10% in the past 24 hours and over 5% this week. The price has steadily trended downward for weeks and shows no clear signs of recovery. At the time of writing, ETH is trading at $3,200, down more than 35% from the ATH levels above $4,950 set in August this year. 

Dogecoin, while only slightly affected by the broader bearish trend, is now trading at $0.165. It has fallen by approximately 2.3% during the week and by an additional 8% in one day. Collectively, these widespread declines suggest that the market may be experiencing a period of extreme stress, as all three cryptocurrencies have recorded double-digit monthly losses.

BTC trading at $97,158 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Freepik, chart from Tradingview.com

Cardano Price Prediction has assessed ADA testing support around $0.50 after Bitcoin has fallen, while large holders have bought millions of tokens, DeFi TVL has reached a multi-year high, ETF inclusion has broadened exposure and momentum indicators on charts have stayed weak.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The ongoing correction remains the most likely scenario for most of the coins, according to CoinStats.

ADA chart by CoinStatsADA/USDCardano (ADA) is one of the biggest losers today, falling by 9.3%.

Image by TradingViewOn the hourly chart, the price of ADA might have set a local support at $0.4998. If the daily bar closes far from that mark, there is a chance to see a test of the resistance by tomorrow.

Image by TradingViewOn the longer time frame, there are no reversal signals so far. In this case, one should focus on the nearest zone of $0.50. 

You Might Also Like

If the daily bar closes below it, the decline may continue to the $0.48 range. Such a scenario is relevant until the end of the week.

Image by TradingViewFrom the midterm point of view, the rate of ADA keeps going down after a false breakout of the resistance of $0.6884. If the weekly bar closes around the current prices or below, one can expect a test of the $0.4158 level soon.

ADA is trading at $0.5128 at press time.

Michael Saylor, Strategy founder and executive chairman, joins 'Squawk box' to discuss the latest bitcoin price trends, what's behind the recent volatility, Strategy's bitcoin stockpile, long-term outlook, and more.

The U.S. and Switzerland have reached a trade deal, U.S. Trade Representative Jamieson Greer told CNBC on Friday.

Duties will be reduced to 15%, the Swiss government said in a post on X, adding that further details will be announced at 4 p.m. local time.

watch now

Back in July, President Donald Trump announced Switzerland would be hit with a 39% tariff rate, which took hold when a Swiss delegation failed to secure a deal with U.S. officials during last-ditch talks in Washington.

This is a breaking news story. Please refresh for updates.

PARIS--(BUSINESS WIRE)--During the United Nations Climate Change Conference (COP 30) taking place in Belém, Brazil, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE), a member of the Oil and Gas Climate Initiative (OGCI) and of the Oil and Gas Decarbonization Charter (OGDC), announces a $100 million commitment to Climate Investment's Venture Strategy fund, which backs technologies that cut emissions across the oil and gas value chain. Climate Investment is now a Partner of the Oil & Gas Decarb.

Financing facility supports conversion of more than $50 million in contracted school bus orders, with over 130 chassis already produced to accelerate revenue recognition and improve working-capital efficiency.
Early production work positions GreenPower for improved gross margins and a pathway to positive operating cash flow.
, /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ: GP) ("GreenPower" or the "Company") today announced accelerated production of its all-electric school bus lineup, supported by a financing facility of up to $18 million, deployable in tranches of up to $2 million. The facility is designed to optimize cash conversion cycles, enabling GreenPower to match capital deployment with production timing as the Company scales output.

GreenPower’s Type A Nano BEAST and Type D BEAST school buses.

"We are entering a period of meaningful operational leverage," said Fraser Atkinson, CEO of GreenPower. "With more than $50 million in contracted orders for our Nano BEAST and BEAST school buses, this facility allows us to convert backlog into deliveries more efficiently. Before finalizing the facility, we pre-built over 100 Nano BEAST cab chassis and 30 BEAST chassis, significantly reducing production lead times. This creates a clear path toward accelerated revenue recognition, margin expansion, and improved operating cash flow."

GreenPower remains the only fully electric OEM manufacturing both a Class 4 Type A and Class 8 Type D school bus. This vertically integrated, purpose-built platform strategy positions the Company to capture share as the school transportation sector transitions to zero-emission fleets supported by federal and state incentives.

For further information contact:

Fraser Atkinson, CEO
(604) 220-8048
[email protected]  

Michael Sieffert, CFO
[email protected]  

Brendan Riley, President
[email protected] 

About GreenPower Motor Company Inc.

GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van and a cab and chassis.  GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. For further information go to www.greenpowermotor.com 

Forward-Looking Statements

This document contains forward-looking statements relating to, among other things, GreenPower's business and operations and the environment in which it operates, which are based on GreenPower's operations, estimates, forecasts and projections. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "upon", "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations, and include statements regarding Greenpower's plans to accelerate production of its school bus lineup, optimize its cash conversion cycle and revenue recognition. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, such as whether the Company will continue to optimize its operations and focus on initiatives that drive sustainable growth, whether the Company can accelerate production of its school bus lineup to clear the production backlog, or whether the Company will continue to meet all of the requirements to maintain its Nasdaq exchange listing. A number of important factors including those set forth in other public filings  could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. GreenPower disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE GreenPower Motor Company

XPeng (NYSE: XPEV) received a major vote of confidence from Wall Street this week after JPMorgan analyst Nick Lai doubled the firm’s price target to $50, up from $25, while maintaining an Overweight rating.

The new target given on Friday implies nearly 90% upside from current levels at marker open of $26.38 and arrives just days before the company releases its Q3 2025 earnings on November 17.

XPeng shares are up 123% year-to-date, supported by rising deliveries, expanding revenue, and new vehicle launches that have kept the brand competitive in China’s crowded EV market.

Morgan Stanley had already taken an upbeat stance earlier in the month. On November 11, 2025, the bank reaffirmed a $34 price target with a Buy rating, signaling 28.9% upside over the next year.

Elsewhere, Bernstein SocGen Group on November 6, 2025 maintained a Hold rating and set a $21 price target, implying a 20.39% downside from current levels.

XPeng is becoming a leader in innovation
Innovation has played a major role in XPeng’s rally. The company held its 2025 AI Day on November 5, unveiling updates to its autonomous driving stack, advancements in “Physical AI,” and early plans across robotaxis, humanoid robots, and eVTOL aircraft.

Momentum accelerated on November 11, when XPeng showcased progress on its IRON humanoid robot and enhancements to its robotaxi ecosystem, pushing the stock to a three-year high.

Although many of these projects remain in early development, they have strengthened XPeng’s narrative as a technology-driven automaker with ambitions extending far beyond traditional EVs. The upcoming earnings report will provide clarity on whether operational performance can keep pace with the company’s rapid innovation cycle.

Wall Street forecasts XPeng earnings
Analysts expect XPeng to post a $0.05 per-share loss for the quarter, a significant improvement from the $0.27 loss a year earlier. Revenue is projected to reach $2.86 billion, an increase of 103% year over year. It’s also worth highlighting that the electric vehicle (EV) company has also beaten EPS estimates for seven consecutive quarters, reinforcing expectations for another strong performance.

Investors will now look to the Q3 earnings call for updated delivery guidance and more detail on how XPeng plans to commercialize its emerging AI and robotics platforms.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Significant Losses In Nidec To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). 

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nidec Corporation ("Nidec" or the "Company") (OTC: NJDCY).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP)

On September 3, 2025, Nidec disclosed it had established a third-party committee to investigate suspicions of improper accounting. The Company further revealed its "investigations found multiple documents suggesting that . . . the Company and its group companies could have engaged in improper accounting with the involvement or knowledge of its or their management[.]"

On this news, Nidec's stock price fell $0.81, or 16.5%, to close at $4.11 per share on September 4, 2025, thereby injuring investors.

Then, on September 26, 2025, Nidec disclosed further investigative findings of additional suspected inappropriate accounting practices, including "cases where the reported value for customs purposes was declared to be lower than the appropriate amount without legitimate reason." The Company also revealed that it "received an audit report containing a disclaimer of opinion" from its auditor due to the "ongoing investigations by the third-party committee, other internal investigations, and other action[s]."

On this news, Nidec's stock price fell $0.29, or 6.6%, to close at $4.09 per share on September 26, 2025.

Then, on October 23, 2025, Nidec published a press release announcing that it was withdrawing its year end forecast, and had decided not to pay a surplus dividend as "investigations by the Third Party Committee regarding suspected inappropriate accounting practices involving the Company and its group, as well as other internal investigations, are ongoing."

On this news, Nidec's stock price fell $1.17, or 25.4%, to close at $3.43 on October 23, 2025.

Finally, on October 27, 2025, the Tokyo Stock Exchange ("TSE") designated Nidec under a Special Security alert in part because "TSE deems that the improvement of the internal management system of said listed company is highly necessary." The alert noted that "[s]ince the initial issue was discovered, the scope of the investigation has continued to expand" and that "deficiencies have already been identified in the Company's company-wide internal control systems (particularly in areas related to information and communication), as well as in the internal controls related to its accounting and financial closing processes."

On this news, Nidec's stock price fell $0.80, or 20.3%, to close at $3.15 per share on October 27, 2025, thereby injuring investors further.

To learn more about the Nidec investigation, go to www.faruqilaw.com/NJDCY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Investors in Farmers National Banc Corp. (FMNB - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 19, 2025 $2.50 Call had some of the highest implied volatility of all equity options today. 

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for Farmers National Banc shares, but what is the fundamental picture for the company? Currently, Farmers National Banc is a Zacks Rank #3 (Hold) in the Banks – Midwest industry that ranks in the Top 11% of our Zacks Industry Rank. Over the last 30 days, two analysts have increased their earnings estimates for the current quarter, while none have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from 42 cents per share to 47 cents in that period.

Given the way analysts feel about Farmers National Banc right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.

Click to see the trades now >>

The Zacks Automotive - Original Equipment industry islikely to benefit from a broad range of product and service offerings as well as strategic partnerships. The Trump administration’s new tax incentive for car buyers is likely to boost demand for vehicles and, consequently, the equipment required to build new vehicles. Demand for advanced electrical and electronic systems, which are high-margin, can help equipment manufacturers improve profitability. Auto equipment manufacturers, such as Magna International Inc. (MGA - Free Report) , QuantumScape Corporation (QS - Free Report) and Luminar Technologies, Inc. (LAZR - Free Report) , are poised to benefit meaningfully from this accelerating wave of demand.

Industry Description
The Zacks Automotive - Original Equipment Industry comprises companies that design, produce and provide passive safety systems for the automotive sector. These systems aim to improve safety, boost efficiency, reduce overall ownership costs and streamline fleet management, supporting individuals who tackle some of the toughest jobs globally. Companies that design, engineer and manufacture Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles are also part of the same industry. The industry supplies equipment to the U.S. government and big car manufacturers. Some companies also engage in equipment financing and leasing solutions for their customers, primarily through third-party funding arrangements.

Factors Influencing the Outlook of the Original Equipment Industry
Tax Incentives Aim to Boost Demand for Vehicles:The Trump administration’s “One Big Beautiful Bill Act” would grant qualifying car buyers a tax deduction of up to $10,000 on interest paid for new U.S.-assembled vehicles, per Forbes. The deduction excludes leases and commercial vehicles and phases out for individuals earning more than $100,000 or $200,000 for a joint filer. With the average new vehicle costing $48,000 and loan rates around 8.64%, a buyer paying $2,000 in yearly interest could save about $400 per year or $2,000 over a five-year loan. These savings will help offset potential price increases tied to Trump’s import tariffs. The bill will likely encourage more people to buy new cars and increase demand for equipment required to build new vehicles.

Rising Need for Advanced Electronics Lifts OEM Opportunities:Demand for advanced electrical and electronic systems, such as ADAS, infotainment and connectivity features, is rising. These technologies improve vehicle safety, convenience and the overall user experience, making them important differentiators in a competitive market. As a result, OEMs can supply more high-value components per vehicle. Since advanced electronics typically offer higher margins than traditional mechanical parts, suppliers that can produce these systems stand to benefit through improved profitability.

Protectionist Tariffs Drive Up Costs for Auto Equipment Makers:The U.S. government has taken a protectionist stance to encourage automakers to expand domestic manufacturing. Protectionism involves restricting foreign trade through measures like tariffs, quotas and subsidies to support local industries. Beginning in May 2025, the government imposed a 25% tariff on imported engines, transmissions, and other key auto parts. This has increased costs for equipment manufacturers.

Zacks Industry Rank Indicates Upbeat Near-Term Prospects
The Zacks Automotive - Original Equipment Industry is part of the broader Zacks Autos/ Tires/ Trucks sector. It carries a Zacks Industry Rank #89, which places it in the top 37% of more than 250 Zacks industries.

The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates upbeat near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.

The industry’s position in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are optimistic about this group’s earnings growth potential.

Based on the positive industry outlook, we will present a few stocks that you might consider adding to your watchlist. Before that, let’s discuss the industry’s recent stock market performance and valuation picture.

Industry Lags the S&P 500 & Sector
The Zacks Automotive - Original Equipment Industry has underperformed the S&P 500 and its sector over the past year. The industry has returned 2.9% over this period compared with than the S&P 500’s growth of 19.1%. The broader sector has returned 24.5% in the same time frame.

One-Year Price Performance
Image Source: Zacks Investment Research

Industry's Current Valuation
Since automotive companies are debt-laden, it makes sense to value them based on the Enterprise Value/ Earnings before Interest Tax Depreciation and Amortization (EV/EBITDA) ratio.

Based on the trailing 12-month enterprise value to EBITDA (EV/EBITDA), the industry is currently trading at 17.33X compared with the S&P 500’s 18.59X and the sector’s 23.51X.

Over the past five years, the industry has traded as high as 22.17X and as low as 8.07X, with the median being 13.51X, as the chart below shows.

EV/EBITDA Ratio (Past 5 Years)
Image Source: Zacks Investment Research

Image Source: Zacks Investment Research

3 Stocks to Consider Right Now
Magna: It is a mobility technology company and global automotive supplier that offers comprehensive vehicle engineering and contract manufacturing expertise. Its broad range of product and service offerings minimizes its risk exposure. The company is actively focusing on innovation and technology development, along with program launches across its business segments and stands to benefit from key emerging trends, including electrification and autonomous driving. Magna is steadily securing new business, which bodes well for its top-line growth. 

MGA currently carries a Zacks Rank #2 (Buy) and has a Value Score of A. Magna has surpassed estimates in three of the trailing four quarters and missed once, the average earnings surprise being 7.67%. The Zacks Consensus Estimate for MGA’s 2025 and 2026 EPS has improved 21 cents and 15 cents, respectively, in the past 30 days.

Price & Consensus: MGA

Image Source: Zacks Investment Research

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

QuantumScape: It is a battery developer for electric vehicles. Its big breakthrough came with its Cobra separator process, a next-generation manufacturing method that could make solid-state batteries commercially viable. The company announced in June that Cobra had successfully entered baseline cell production. Another turning point came with QuantumScape’s public demonstration of its technology at the IAA Mobility show in Munich, held in September. The company, together with Volkswagen’s VWAGY battery arm PowerCo, showcased a Ducati MotoE race bike powered by QuantumScape’s QSE-5 solid-state cells. 

QS currently carries a Zacks Rank #2. QuantumScape has surpassed estimates in one of the trailing four quarters and matched thrice, the average earnings surprise being 1.09%. The Zacks Consensus Estimate for 2025 EPS implies year-over-year growth of 21.3%. The Zacks Consensus Estimate for QS’ 2025 and 2026 EPS has narrowed 4 cents each in the past 30 days.

Price & Consensus: QS

Image Source: Zacks Investment Research

Luminar: It is an autonomous vehicle sensor and software company. Its LiDAR technology has been adopted in the Volvo EX90 and ES90, making it the first high-performance LiDAR integrated as standard in a global production vehicle. Partnerships with Nissan and Mercedes-Benz further highlight its strong automotive positioning, which is critical as automakers move toward higher levels of autonomy. LAZR is also diversifying into commercial and defense markets, where adoption is progressing more quickly. Its 1550-nanometer LiDAR is being tested for military and drone applications, areas that could bring earlier revenue opportunities and stronger unit economics than passenger cars. This diversification provides a meaningful hedge while waiting for mass consumer adoption.

LAZR currently carries a Zacks Rank #2. Luminar has surpassed estimates in three of the trailing four quarters and missed once, the average earnings surprise being 2.98%. The Zacks Consensus Estimate for 2025 EPS implies year-over-year growth of 52.2%. The Zacks Consensus Estimate for LAZR’s 2025 and 2026 EPS has narrowed 37 cents and $1.19, respectively, in the past 30 days.

Price & Consensus: LAZR

Image Source: Zacks Investment Research

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP)

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study. The press release stated that "[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question," that "[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks," and that Jasper was "taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing." Further, the press release revealed that the Company "has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma." Finally, the press release stated that "the Company is halting development in SCID" and, contrary to its prior representation of having a strong balance sheet and a cash runway extending "through the third quarter of 2025," that Jasper "will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses."

On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Jasper's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Jasper Therapeutics, Inc. class action, go to www.faruqilaw.com/JSPR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

Alithya Group (ALYAF - Free Report) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +75.00%. A quarter ago, it was expected that this consulting company would post earnings of $0.04 per share when it actually produced earnings of $0.05, delivering a surprise of +25%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Alithya, which belongs to the Zacks Technology Services industry, posted revenues of $90.26 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.74%. This compares to year-ago revenues of $81.75 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Alithya shares have added about 25.6% since the beginning of the year versus the S&P 500's gain of 14.6%.

What's Next for Alithya?While Alithya has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Alithya was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.05 on $92.41 million in revenues for the coming quarter and $0.21 on $368.16 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Technology Services is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, MindWalk Holdings Corp. (HYFT - Free Report) , is yet to report results for the quarter ended October 2025.

This company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of +85.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

MindWalk Holdings Corp.'s revenues are expected to be $4 million, down 10.9% from the year-ago quarter.

Key Takeaways DraftKings' Q3 results were hit by clustered NFL outcomes that drove significant sportsbook volatility.DraftKings logged 10% Q3 handle growth and 17% October gains, reflecting resilient customer engagement.DraftKings trimmed its FY25 revenue and EBITDA outlook as outcome-driven pressure weighed on the quarter.
DraftKings Inc. (DKNG - Free Report) is contending with one of the most pronounced periods of sportsbook volatility in recent memory, and the past quarter underscored just how quickly customer-favorable outcomes can distort results. With more than $300 million in revenue impact tied to a concentrated stretch of NFL games across September and October, the company’s short-term performance reflected pressures that masked underlying operational strength. Yet even as DraftKings absorbed these swings, management emphasized that the core fundamentals — handle growth, product depth and retention improvements — remain intact and are critical to sustaining long-term margin progression.

In the third quarter of fiscal 2025, DraftKings delivered 10% Sportsbook handle growth, followed by 17% growth in October, demonstrating resilient engagement despite headline volatility. These gains came alongside improved NFL and NBA activation, with retention metrics advancing year over year. But the quarter’s revenue profile was shaped primarily by customer-friendly outcomes, leading DraftKings to revise its fiscal 2025 outlook to $5.9-$6.1 billion in revenues (compared with the prior expectation of $6.2-$6.4 billion) and $450-$550 million in adjusted EBITDA (compared with the prior expectation of $800-$900 million). The outcome impact stands in sharp contrast to the fiscal second quarter, when favorable events contributed approximately $100 million in additional revenues and supported record profitability.

Management noted that rising parlay mix — while structurally positive for long-term margin — also amplifies periodic variance when outcomes cluster within a narrow window. This has been evident across the sector, but DraftKings’ national scale means swings can be more visible in quarterly reporting. Even so, the company continues to lean on disciplined liability controls, selective hedging and improved risk management tools to moderate exposure without constraining growth.

Regulatory dynamics add complexity, including state-level tax changes and ongoing promotional limitations that vary across markets. But DraftKings reiterated that its long-term model is designed to withstand outcome-driven noise, supported by expanding customer cohorts, higher structural hold and more efficient marketing deployment.

As DraftKings navigates one of the most volatile stretches of the year, the central question is less about the temporary impact of outcomes and more about the durability of the company’s structural advantages. With strong engagement trends, a growing product ecosystem and disciplined cost management, DraftKings is positioning itself to offset periodic swings while reinforcing the long-term economics of its sportsbook model.

DKNG’s Price Performance, Valuation & EstimatesDraftKings’ shares have declined 34% in the past three months compared with the industry’s fall of 4.2%. In the same time frame, other industry players like Accel Entertainment, Inc. (ACEL - Free Report) and Boyd Gaming Corporation (BYD - Free Report) have declined 7.9% and 2.3%, respectively, while Melco Resorts & Entertainment Limited (MLCO - Free Report) has gained 5%.

DKNG Three-Month Price Performance
Image Source: Zacks Investment Research

DKNG stock is currently trading at a discount. It is currently trading at a forward 12-month price-to-sales (P/S) multiple of 2.05, well above the industry average of 2.75. Conversely, industry players, such as Accel Entertainment, Melco Resorts and Boyd Gaming have P/S ratios of 0.63, 0.71 and 1.64, respectively.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for DraftKings’ 2025 earnings per share has declined 22.1% to $1.13 in the past 60 days.

Image Source: Zacks Investment Research

The company is likely to report strong earnings, with projections indicating a 207.6% rise in 2025. Conversely, industry players like Melco Resorts and Boyd Gaming are likely to witness a rise of 157.9% and 8.7%, respectively, year over year in 2025 earnings. Meanwhile, Accel Entertainment's earnings are likely to decline 38.5% year over year in 2025.

DKNG currently carries a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of Autoscope Technologies Corporation (AATC - Free Report) have declined 3.6% since releasing third-quarter 2025 results, lagging the S&P 500 index’s 0.8% growth over the same period. Over the past month, the stock has fallen 4.2%, while the S&P 500 has climbed 3.6%, reflecting investor disappointment following a sharp year-over-year revenue downturn and a swing to a quarterly loss.

In the third quarter, revenues from operations totaled $1.9 million, down 45% from $3.4 million a year earlier, while royalty revenues, historically the company’s largest contributor, also fell 44% to $1.9 million. The company reported a net loss of $0.2 million, or 4 cents per share, against net income of $1.3 million, or 25 cents per share, a year ago.

Management attributed the earnings deterioration to sharply lower revenues and a one-time non-cash foreign currency adjustment from the closure of foreign subsidiaries. Excluding this item, net income would have been $0.2 million.

Other Key Business MetricsThe company’s revenue contraction stemmed largely from high inventory levels at channel partners and customer transitions to the new Autoscope OptiVu platform. Product sales fell sharply, totaling just $15,000 in the quarter versus $50,000 a year ago. Gross profit dropped accordingly, landing at $1.8 million compared with $3.2 million in the prior-year period. Operating expenses held steady at $1.6 million, reflecting stable spending despite the significant decrease in revenues.

Non-GAAP income from operations, which excludes amortization and depreciation, was $0.3 million, far below the $1.8 million recorded in the prior-year quarter. This measure continues to track declines in revenues, as operating costs have not adjusted meaningfully in the short term.

Cash and liquid investments totaled $2.7 million at the quarter-end, rising from $2.6 million at the end of the second quarter but down substantially from $7.4 million at the end of 2024. The decline primarily reflects the $5.8-million special dividend paid out in February 2025.

Management CommentaryInterim CEO Andy Markese emphasized that the quarter’s weaker results reflect a transitional phase as customers migrate from the legacy Autoscope Vision platform to the OptiVu product line. He noted that inventory levels at distributors have normalized and that agency evaluations and procurement processes for OptiVu are progressing. Management expects these dynamics to support a return to “more typical royalty performance” in the fourth quarter.

The commentary underscores management’s belief that recent revenue weakness is primarily cyclical and linked to product transition rather than structural deterioration in demand. Still, the extent of the revenue decline suggests that normalization will be crucial to improving profitability in the coming quarters.

Factors Influencing the Headline NumbersInventory Drawdowns & Product Transition: Revenues from operations and royalty revenues dropped 45% and 44% year over year, respectively. This decrease stemmed from channel partners reducing elevated inventory levels and customers shifting to the OptiVu platform. These factors reduced throughput in the company’s licensing arrangement and contributed heavily to the swing to a quarterly net loss.

One-Time Foreign Currency Loss: The company’s decision to close its Canada and Spain subsidiaries triggered a $0.6-million reclassification of foreign currency translation losses from Accumulated Other Comprehensive Loss to earnings. This non-cash charge pushed the company into a quarterly loss. There was no comparable item in the prior year. Excluding these charges, AATC would have reported a net income of $0.2 million.

ViewManagement’s commentary suggested expectations for improved royalty performance in the fourth quarter as distributor inventories reach more normalized levels and as adoption of the OptiVu platform accelerates. While not quantified, this qualitative signal indicates management’s view that revenue trends may stabilize in the near term.

Other DevelopmentsIn the quarter, Autoscope initiated the closure of its subsidiaries in Canada and Spain. This move resulted in the aforementioned $0.6-million non-cash loss due to the reclassification of cumulative translation losses. The company did not report acquisitions or divestitures beyond these closures. Additionally, the board declared a quarterly dividend of 15 cents per share, payable Nov. 24, 2025, to shareholders of record as of Nov. 17.

Partnership Designed to Help Fathom Clients Enjoy a Seamless Moving Process

, /PRNewswire/ -- Fathom Holdings Inc. (Nasdaq: FTHM), a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings, today announced a strategic partnership with Move Concierge, a leading moving services provider.

This partnership will give Fathom agents and their clients access to Move Concierge's five-star, white-glove concierge services, enhancing the overall experience and providing a seamless moving process. Move Concierge has been trusted for more than 16 years, serving over 250,000 customers with an average satisfaction rating of 4.9 stars. This collaboration reflects Fathom's commitment to innovation, technology, and making every step of the homeownership journey simpler and more efficient for agents and their clients alike.

"We're excited to partner with the team at Move Concierge. Moving is often one of life's more stressful experiences, but Move Concierge's dedicated team helps ease that burden through personalized, white-glove services," said Marco Fregenal, CEO of Fathom Holdings. "This partnership reflects Fathom's commitment to continually evolve our offerings and provide exceptional value to our agents and their clients.

"By integrating Move Concierge into our platform, we're not only enhancing the moving experience but also taking another step toward becoming a true one-stop shop for all homeownership needs. Partnerships like this help us advance the industry and better serve everyone who relies on Fathom."

Gabe Abshire, CEO and Founder, added: "We are excited to this new partnership and be able to offer our services to Fathom and its 15,000 agents. Since 2009, our number one priority has been making the process of moving easier. We help our customers set up their home services with just a quick phone call. With your personal concierge, all you have to do is tell us the services on your list and we'll take care of the rest! This partnership will blend seamlessly with Fathom's full-service, tech-driven platform, making the entire moving process more complete for agents and their clients."

About Move Concierge

Move Concierge is a revolutionary service for connecting utilities and home services like TV, internet, phone, home automation and security. The company's no-cost, white-glove service provides clients with a personal concierge to customize a whole-home connection plan, place orders and schedule installations for each service — all with a single point of contact. Since its founding in 2009, the company has been dedicated to surpassing great customer service, setting the bar by providing a mind-blowing client experience. Move Concierge was named one of the fastest-growing companies in the U.S. by Inc. Magazine.

About Fathom Holdings Inc.

Fathom Holdings Inc. is a national, technology-driven real estate services platform that integrates residential brokerage, mortgage, title, and SaaS offerings through its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.

Investor Contact:

Matt Glover and Clay Liolios
Gateway Group, Inc.
949-574-3860
[email protected] 

SOURCE Fathom Holdings Inc.

Hong Kong, Nov. 14, 2025 (GLOBE NEWSWIRE) -- SOLOWIN HOLDINGS (NASDAQ: AXG) (“Solowin” or the “Company”), a leading financial technology firm bridging traditional and digital assets, today announced that its subsidiary, Solomon JFZ (Asia) Holdings Limited (“Solomon JFZ”), has been selected by the Hong Kong Monetary Authority (“HKMA”) as an industry pioneer in the pilot phase of Project Ensemble (EnsembleTX), an initiative aiming to enable real-value transactions involving tokenized deposits and digital assets within a controlled pilot environment.

Solowin is listed in Annex B of EnsembleTX, which names the participating industry pioneers. Other notable participants include Ant International, Bosera Asset Management (International) Co., Limited, China Asset Management (Hong Kong) Limited, and Hong Kong Exchanges and Clearing Limited (HKEX), among others.

Under EnsembleTX, Solomon JFZ will collaborate with other leading institutions to facilitate interbank transactions involving tokenized deposits and tokenized fund subscriptions through the HKMA’s innovative blockchain-based infrastructure. The initiative aims to demonstrate how monetary and asset tokenization can enhance interoperability, efficiency, and automation across the financial ecosystem, establishing a strong foundation for the future development of a tokenized economy.

According to the HKMA, EnsembleTX builds upon the successful outcomes of the Ensemble Sandbox experimentation. The pilot is designed to enable faster, more transparent, and more efficient settlement of real-value tokenized transactions. Its initial focus will be on empowering market participants to use tokenized deposits in tokenized money market fund transactions and to manage liquidity and treasury operations in real time. This milestone marks Hong Kong’s transition from proof-of-concept to real-value transaction applications in its rapidly evolving tokenization ecosystem.

Dr. Haokang Thomas Zhu, Director of Solowin, commented: “We are honored that our Hong Kong-based crypto-enabled brokerage, Solomon JFZ, has been selected to participate in EnsembleTX, following our earlier participation in the sandbox phase of HKMA’s Project Ensemble. Since the project’s inception in 2024, we have worked closely with the HKMA, as well as various banks and fund houses, to advance sandbox trials. We have witnessed firsthand the tremendous potential of tokenized deposits in driving financial innovation, and we look forward to further expanding their practical applications, including in fund settlement, in 2026.”

About SOLOWIN HOLDINGS

SOLOWIN HOLDINGS (NASDAQ: AXG) is a global leading financial technology firm focused on digital currency payments and asset tokenization. Founded in 2016, it has dedicated to bridging traditional and decentralized finance by building a secure, efficient and compliant financial infrastructure that provides integrated digital asset solutions for global investors and institutions. Leveraging its Hong Kong Securities and Futures Commission (SFC)-licensed subsidiary Solomon JFZ (Asia) Holdings Limited, along with other key subsidiaries such as AlloyX Group and AX Coin HK Limited, the Company has developed a multi-jurisdictional, vertically integrated, enterprise-grade new financial platform encompassing global stablecoin payments, corporate treasury and private wealth management and real-world asset (RWA) tokenization. Backed by leading international institutional investors, the Company manages compliant and transparent digital assets that are closely connected to the real economy. The Company is committed to establishing itself as a leading global digital asset financial platform, driving the seamless convergence of traditional finance and the Web3 ecosystem.

For more information, visit the Company’s website at https://www.alloyx.com or investor relations webpage at https://ir.solowin.io.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company has attempted to identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (the “SEC”) including the "Risk Factors" section of the Company's most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC, which are available for review at www.sec.gov.
For investor and media inquiries please contact:

SOLOWIN HOLDINGS
Investor Relations Department
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data –

– Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting –

– Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 –

IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced its financial results for the quarter ended September 30, 2025, and provided a business update.

“The foundation of AEON’s progress lies in our science and is underscored by years of market validation”, said Rob Bancroft, AEON’s President and Chief Executive Officer. “Our recently released analytical results confirm both ABP-450’s identical amino-acid sequencing of all visible portions and highly similar functional characteristics to BOTOX®. These results are supported by a globally approved and fully scaled manufacturing platform with approvals in 69 countries. Together, these scientific and global data points validate our biosimilar strategy and instill confidence in AEON’s path forward.”

“On the strength of this foundation, we announced two complementary financing transactions with Daewoong Pharmaceutical and institutional investors that are expected to eliminate over 90% of our outstanding debt, strengthen our balance sheet, and extend our cash runway into the second quarter of 2026 while accelerating the ABP-450 program by up to six months. With our FDA Type 2a meeting scheduled later this month, we are entering the next phase of development from a position of scientific and financial strength.”

Recent Clinical and Corporate Highlights

Positive Biosimilarity Results In November 2025, AEON reported positive biosimilarity data for ABP-450, its proposed biosimilar to BOTOX®. Analytical results confirmed identical amino-acid sequencing and highly similar functional characteristics to BOTOX®. The analytical package has been submitted to the FDA ahead of AEON’s Type 2a meeting scheduled for November 19, 2025. LC-MS analysis demonstrated that the primary structure of ABP-450 exhibited a 100% amino-acid sequence match to BOTOX®, with sequence coverage of 93–99% across all five proteins comprising the 900 kDa botulinum toxin type A complex. Strategic Financing and Note Exchange Also in November 2025, AEON announced two complementary transactions - a $6 million PIPE financing and a proposed Daewoong Pharmaceutical note exchange - which, together, are expected to strengthen AEON’s balance sheet, reduce outstanding debt by more than 90% and extend cash runway into the second quarter of 2026 while accelerating the ABP-450 program by up to six months. Liquidity and Capital Resources

The Company reported cash and cash equivalents of $5.9 million as of September 30, 2025, which does not include expected proceeds from the November 2025 PIPE financing. Including the recent financing, the company’s cash and cash equivalents are expected to be sufficient to fund the Company’s operating plan through into the second quarter of 2026, well beyond its Type 2a meeting with the FDA scheduled for this month. Expected Upcoming Milestones

November 19, 2025 – Expected results and path forward from Biosimilar Biological Product Development (BPD) Type 2a FDA meeting. About the U.S. Biosimilar Pathway

The U.S. Food and Drug Administration (“FDA”) regulates biosimilars under the Public Health Service Act’s 351(k) pathway, which require developers to demonstrate that a proposed product is highly similar to an approved reference biologic with no clinically meaningful differences in safety, purity, or potency. Analytical similarity is the scientific foundation of this process, representing the most critical and data-intensive phase of development. Once analytical comparability across key quality attributes is established, subsequent FDA interactions focus on confirming whether any residual uncertainty requires limited clinical evaluation.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. The Company’s lead asset is ABP-450 injection for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of completion of, or outcome of results from, primary comparative analytical studies, or potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan", "possible", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the completion of the primary structure analysis by AEON; (ii) the completion of select functional analyses by Daewoong Pharmaceutical; (iii) the expected Type 2a meeting with the FDA and potential path forward to biosimilarity designation; (iv) AEON’s ability to receive full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX on an accelerated timeline or at all; (v) the outcome of any legal proceedings that may be instituted against AEON or others; (vi) AEON’s future capital requirements; (vii) AEON’s ability to raise financing in the future; (viii) AEON’s ability to continue to meet continued stock exchange listing standards; (ix) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (x) the outcomes from any meetings or discussions with regulatory authorities; (xi) the timing of, or results from, any testing performed on AEON’s product; (xii) AEON’s ability to consummate the PIPE financing transaction and proposed notes exchange transaction in a timely manner and on the current terms; and (xiii) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC’s website at www.sec.gov.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.

Additional Information and Where to Find It

This press release may be deemed to be solicitation material in respect of obtaining the stockholder approval needed to consummate the PIPE financing and proposed not exchange transactions described above (the “Stockholder Approval”). In connection with obtaining the Stockholder Approval, the Company expects to file a proxy statement on Schedule 14A and other relevant materials with the SEC. This communication does not constitute a solicitation of any vote or approval. SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY ALL RELEVANT DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC, INCLUDING THE COMPANY’S PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTIONS. Copies of the proxy statement and other relevant materials and any other documents filed by the Company with the SEC may be obtained free of charge at the SEC’s website, at www.sec.gov. In addition, stockholders may obtain free copies of the proxy statement and other relevant materials through the website maintained by the SEC at http://www.sec.gov. or by directing a request to: AEON Biopharma, Inc., [email protected].

Participants in the Solicitation

The Company and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in respect of the Stockholder Approval. Information about the directors and executive officers of the Company is set forth in the Company's proxy statement on Schedule 14A filed with the SEC on April 29, 2025 and on subsequent Form 4 and Form 5 filings. Other information regarding the persons who may be deemed participants in the proxy solicitations in connection with the transactions, and a description of any interests that they have in the exchanges, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the Stockholder Approval when they become available. Stockholders, potential investors and other interested persons should read the proxy statement carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

Contacts

Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
[email protected]

Source: AEON Biopharma

 AEON BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data and par value amounts)  September 30, December 31, 2025
 2024
 (Unaudited)  ASSETS     Current assets:     Cash and cash equivalents$5,927  $13 Prepaid expenses and other current assets 1,485   1,577 Total current assets 7,412   1,590 Property and equipment, net 181   235 Operating lease right-of-use asset 1,112   1,288 Other assets 29   29 Total assets$8,734  $3,142 LIABILITIES AND STOCKHOLDERS' DEFICIT     Current liabilities:     Accounts payable$2,525  $5,910 Accrued clinical trials expenses 1,524   3,571 Accrued compensation 1,547   1,068 Other accrued expenses 2,632   3,600 Total current liabilities 8,228   14,149 Convertible notes at fair value, including related party amount of
$17,051 and $11,689, at September 30, 2025 and December 31, 2024,
respectively 17,051   11,689 Operating lease liability 957   1,145 Warrant liability 2,338   1,187 Contingent consideration liability 32   3,541 Total liabilities 28,606   31,711 Commitments and contingencies (Note 6)     Stockholders’ Deficit:     Class A common stock, $0.0001 par value; 1,040,000,000 and
500,000,000 shares authorized at September 30, 2025 and
December 31, 2024, and 11,643,786 and 555,511 shares issued and
outstanding at September 30, 2025 and December 31, 2024, respectively 9   4 Additional paid-in capital 413,801   403,024 Accumulated deficit (433,682)  (431,597)Total stockholders' deficit (19,872)  (28,569)Total liabilities and stockholders' deficit$8,734  $3,142          AEON BIOPHARMA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME(in thousands, except share and per share data)  Three Months Ended Nine Months Ended September 30, September 30, 2025
 2024
 2025
 2024
Operating expenses:           Selling, general and administrative$1,933  $3,044  $8,316  $11,014 Research and development 597   972   2,485   11,144 Change in fair value of contingent consideration (37)  —   (3,509)  (97,464)Total operating costs and expenses 2,493   4,016   7,292   (75,306)(Loss) income from operations (2,493)  (4,016)  (7,292)  75,306 Other (loss) income:           Change in fair value of convertible notes (1,877)  (1,878)  (5,362)  (170)Change in fair value of warrants (236)  (377)  85,950   (15,376)Loss on issuance of warrants —   —   (75,644)  — Loss on embedded forward purchase agreements
and derivative liabilities, net —   81   —   (19,931)Other income, net 68   19   263   94 Total other (loss) income, net (2,045)  (2,155)  5,207   (35,383)(Loss) income before taxes (4,538)  (6,171)  (2,085)  39,923 Income taxes —   —   —   — Net (loss) income$(4,538) $(6,171) $(2,085) $39,923 Basic net (loss) income per share$(0.39) $(11.24) $(0.23) $74.53 Diluted net (loss) income per share$(0.39) $(11.24) $(0.23) $69.53 Weighted average shares of common stock
outstanding used to compute basic net (loss) income
per share 11,634,946   549,175   8,931,566   535,693 Weighted average shares of common stock
outstanding used to compute diluted net (loss)
income per share 11,634,946   549,175   8,931,566   574,216                  The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its controlled subsidiaries.

-

PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (NYSE: CNK), one of the largest motion picture exhibitors in the world, today announced participation at the following institutional investor conferences:

Tuesday, November 18: Wells Fargo TMT Conference in Rancho Palos Verdes, CA

Melissa Thomas, CFO; Chanda Brashears, SVP Investor Relations

1:1 investor meetings

Fireside chat at 1:30 pm PT

https://cc.webcasts.com/well001/111825a_js/?entity=35_YDSUQJC

About Cinemark Holdings, Inc.:

Cinemark Holdings, Inc. (NYSE: CNK) provides extraordinary out-of-home entertainment experiences as one of the largest and most influential theatrical exhibition companies in the world. Based in Plano, Texas, Cinemark makes every day cinematic for moviegoers across nearly 500 theaters and over 5,500 screens, operating in 42 states in the U.S. (304 theaters; 4,249 screens) and 13 South and Central American countries (193 theaters; 1,395 screens). Cinemark offers guests superior sight and sound technology, including Barco laser projection and Cinemark XD, the world’s No. 1 exhibitor-branded premium large format; industry-leading penetration of upscale amenities such as expanded food and beverage offerings, Luxury Lounger recliners and D-BOX motion seats; top-notch guest service; and award-winning loyalty programs such as Cinemark Movie Club. All of this creates an immersive environment for a shared, entertaining escape, underscoring that there is no place more cinematic than Cinemark. For more information, visit https://ir.cinemark.com.

More News From Cinemark Holdings, Inc.

Back to Newsroom

Decades after their founders connected, Apple and Issey Miyake released a collection of phone pouches that have some people baffled. They hope it will inspire creativity.

Key Takeaways Agnico Eagle reported better-than-expected Q3 earnings but faced higher all-in sustaining costs.AEM expects 2025 AISC of $1,250-$1,300 per ounce, up from 2024 as cost pressures persist.Shares have surged 115.9% YTD, with EPS estimates for 2025 and 2026 trending higher.
Agnico Eagle Mines Limited (AEM - Free Report) delivered better-than-expected earnings in the third quarter, but it remains hamstrung by higher unit costs. Its all-in sustaining cost (AISC) — the most important cost metric of miners — was $1,373 per ounce in the third quarter, marking a roughly 6% increase from the prior quarter and a 7% year-over-year rise. AISC increased due to higher total cash costs and an uptick in general and administrative expenses. Total cash costs per ounce for gold were $994, up 8% from $921 a year ago and higher than $933 in the prior quarter.

Higher production costs warrant caution, as they will likely weigh on AEM’s profitability. This calls for prudent cost management to maintain competitiveness and sustain margins. AEM forecasts total cash costs per ounce in the range of $915 to $965 and AISC per ounce between $1,250 and $1,300 for 2025, suggesting a year-over-year increase at the midpoint of the respective ranges.

While Agnico Eagle is taking actions to control costs, the inflationary pressure is likely to continue over the near term, weighing on its overall financial performance. AISC is likely to rise in the latter part of 2025 as deferred expenditures are realized. Maintaining its cost discipline will be crucial for the company to sustain its margin expansion.

Among AEM’s peers, Newmont Corporation (NEM - Free Report) lowered its third-quarter AISC to $1,566 per ounce, marking a 3% decrease from the prior-year quarter and a decline from $1,593 in the prior quarter. This improvement was primarily due to a decline in costs applicable to sales and lower general and administrative expenses, as Newmont is enjoying the benefits from its cost-saving actions. Newmont expects gold AISC for the total portfolio to be $1,630 per ounce in 2025, reflecting a rise from $1,516 per ounce in 2024.

Barrick Mining Corporation (B - Free Report) also saw a 9% sequential decline in AISC in the third quarter, reaching $1,538 per ounce. This downside was driven by lower total cash costs per ounce and lower minesite sustaining capital expenditures. Barrick maintained its cost guidance for the full year. For 2025, Barrick projects AISC in the range of $1,460-$1,560 per ounce, indicating a year-over-year increase at the midpoint.

The Zacks Rundown for AEMShares of Agnico Eagle have shot up 115.9% year to date against the Zacks Mining – Gold industry’s rise of 130.1%, largely driven by the gold price rally.

Image Source: Zacks Investment Research

From a valuation standpoint, AEM is currently trading at a forward 12-month earnings multiple of 19.51, a roughly 46.1% premium to the industry average of 13.35X. It carries a Value Score of C.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for AEM’s 2025 and 2026 earnings implies a year-over-year rise of 82.3% and 20.7%, respectively. The EPS estimates for 2025 and 2026 have been trending higher over the past 60 days.

Image Source: Zacks Investment Research

Key Takeaways Kronos Worldwide reported a Q3 net loss of $37M versus a $71.8M profit in the prior year.Sales fell 6% to $456.9M, driven by weaker TiO2 prices and reduced European and export volumes.Kronos plans further inventory and cost cuts as it braces for softer Q4 and full-year results.
Kronos Worldwide, Inc. (KRO - Free Report) reported a third-quarter 2025 net loss of $37 million or 32 cents per share. This compares unfavorably to profits of $71.8 million, or 62 cents per share in the year-ago quarter.

Barring one-time items, adjusted loss came in at 18 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 6 cents.

Net sales decreased around 6% year over year to $456.9 million. The decline was mainly due to lower average titanium dioxide (TiO2) selling prices and reduced sales volumes in the company’s European and export markets, partly offset by higher sales volumes in the North American market. The top line missed the Zacks Consensus Estimate of $478.5 million.

KRO saw softer customer demand in the reported quarter, continuing the weakness that started earlier this year. High interest rates and economic uncertainties due to trade tensions and tariffs continued to contribute to cautious customer spending.

KRO’s Volumes and PricingTiO2 production volumes (thousand metric tons) were down roughly 11% year over year to 126 in the third quarter. TiO2 sales volumes (thousand metric tons) declined around 3% to 126 in the quarter.

TiO2 segment loss was $15.3 million in the reported quarter compared with a segment profit of $43.4 million a year ago. The downside was mainly due to reduced income from operations as a result of unfavorable fixed cost absorption stemming from reduced operating rates at certain of KRO’s manufacturing facilities and increased cost inventory produced in the second quarter relative to the year-ago quarter.

KRO’s FinancialsKronos ended the quarter with cash and cash equivalents of $27.7 million, up around 47% from the prior quarter. Long-term debt amounted to $626.2 million, up around 25% sequentially.

KRO’s OutlookThe company does not envision sales volumes to improve meaningfully in the near term. It is taking additional actions in the fourth quarter to reduce inventory levels through the reduction of operating rates to better align with current demand levels amid the subdued demand environment. KRO expects these actions to improve operating cash flows as it focuses on boosting liquidity to navigate through the current demand environment. The company is also implementing additional cost reduction initiatives to improve its cost structure.

Kronos anticipates operating results in the fourth quarter to be lower than the third quarter and also expects to report lower year-over-year operating results for full-year 2025, factoring in lower-than-expected demand, continued pricing pressure and lower fixed cost absorption due to reduced operating rates.

KRO’s Zacks Rank & Other Chemical ReleasesKRO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Chemours Company’s (CC - Free Report) third-quarter adjusted earnings were 20 cents per share, which missed the Zacks Consensus Estimate of 24 cents. Chemours expects fourth-quarter net sales to fall 10-15% sequentially due to seasonality.

Element Solutions Inc. (ESI - Free Report) logged third-quarter adjusted earnings per share of 41 cents per share, beating the Zacks Consensus Estimate of 39 cents. ESI anticipates full-year 2025 adjusted EBITDA in the range of $545 million to $550 million.

Huntsman Corporation’s (HUN - Free Report) adjusted loss per share was 3 cents compared with earnings of 10 cents in the year-ago quarter. It was narrower than the Zacks Consensus Estimate of a loss of 13 cents. HUN’s restructuring programs, which are expected to deliver more than $100 million in savings, remain on course and are expected to be completed this year.

Amaroq Ltd. (AMRQ:CA) Q3 2025 Earnings Call November 14, 2025 4:00 AM EST

Company Participants

Edward Westropp - Head of Business Development & Corporate Affairs
Eldur Olafsson - Founder, President, CEO & Director
Ellert Arnarson - Chief Financial Officer
Joan Plant

Presentation

Edward Westropp
Head of Business Development & Corporate Affairs

Good morning, everyone. Welcome to the Q3 2025 results from Amaroq. Thanks for joining. We'll follow the usual call for today. So management will take you through the presentation, and then we'll follow that with Q&A.

First of all, from the line, moderated by Sharon. And then I'll moderate the questions on the web.

So thanks very much for joining. I'll hand over to Eldur Olafsson, the Chief Executive.

Eldur Olafsson
Founder, President, CEO & Director

Thank you, Edward. Good morning, everybody. It's a pleasure to be with you here today after a very busy and successful quarter. I want to start the day up by giving you a snapshot of our operation as we usually do on this quarter. So we are very much focused on our mining development in Greenland, meaning now production, development and exploration. To do that, we are in Greenland. And as you can see, Greenland needs a lot of services and energy to enable these businesses to be successful. And therefore, out of necessity, we have set up this business as well.

We are mainly focused on 2 different regions in Greenland. We are in South Greenland, where you have Gold Belt, you have rare earth, non-rare earth areas and then you have copper and base metals. There, we have the Nalunaq mine. We have the Nanoq exploration development project, and then we have early-stage exploration in Vagar.

In West Greenland, there we have the Black Angel past producing mine, and the intention is to bring that into

Recommended For You